Immunotherapy, especially immune checkpoint inhibitors targeting PD-1/PD-L1, has shown promising results in a variety of tumors (such as lung cancer [25], melanoma [26], kidney cancer [27], bladder cancer [28], colon cancer [29]), and has also achieved good efficacy in OPSCC [30]. This evidence concerns the gene CD274 and lung carcinoma.